Thyrocare Technologies Limited

NSEI:THYROCARE Stock Report

Market Cap: ₹52.6b

Thyrocare Technologies Valuation

Is THYROCARE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of THYROCARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: THYROCARE (₹972.25) is trading above our estimate of fair value (₹716.42)

Significantly Below Fair Value: THYROCARE is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for THYROCARE?

Key metric: As THYROCARE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for THYROCARE. This is calculated by dividing THYROCARE's market cap by their current earnings.
What is THYROCARE's PE Ratio?
PE Ratio61.4x
Earnings₹839.60m
Market Cap₹52.57b

Price to Earnings Ratio vs Peers

How does THYROCARE's PE Ratio compare to its peers?

The above table shows the PE ratio for THYROCARE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average72x
METROPOLIS Metropolis Healthcare
73.6x21.0%₹109.0b
KRSNAA Krsnaa Diagnostics
42.4x35.5%₹29.4b
VIJAYA Vijaya Diagnostic Centre
82.1x25.4%₹108.8b
SURAKSHA Suraksha Diagnostic
89.9xn/a₹21.2b
THYROCARE Thyrocare Technologies
61.4x26.9%₹51.6b

Price-To-Earnings vs Peers: THYROCARE is good value based on its Price-To-Earnings Ratio (61.4x) compared to the peer average (72x).

Price to Earnings Ratio vs Industry

How does THYROCARE's PE Ratio compare vs other companies in the IN Healthcare Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
523696 Fortis Malar Hospitals
2.3xn/aUS$12.87m
No more companies available in this PE range
THYROCARE 61.4xIndustry Avg. 44.5xNo. of Companies9PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: THYROCARE is expensive based on its Price-To-Earnings Ratio (61.4x) compared to the Indian Healthcare industry average (44.5x).

Price to Earnings Ratio vs Fair Ratio

What is THYROCARE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

THYROCARE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio61.4x
Fair PE Ratio58x

Price-To-Earnings vs Fair Ratio: THYROCARE is expensive based on its Price-To-Earnings Ratio (61.4x) compared to the estimated Fair Price-To-Earnings Ratio (57.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst THYROCARE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹972.25
₹1,007.50
+3.6%
3.2%₹1,040.00₹975.00n/a2
Dec ’25₹1,000.35
₹1,007.50
+0.7%
3.2%₹1,040.00₹975.00n/a2
Nov ’25₹927.70
₹1,007.50
+8.6%
3.2%₹1,040.00₹975.00n/a2
Oct ’25₹828.10
₹800.00
-3.4%
3.1%₹825.00₹775.00n/a2
Sep ’25₹861.80
₹800.00
-7.2%
3.1%₹825.00₹775.00n/a2
Aug ’25₹818.00
₹800.00
-2.2%
3.1%₹825.00₹775.00n/a2
Jul ’25₹650.75
₹740.00
+13.7%
1.4%₹750.00₹730.00n/a2
Jun ’25₹612.20
₹740.00
+20.9%
1.4%₹750.00₹730.00n/a2
May ’25₹644.95
₹727.50
+12.8%
0.3%₹730.00₹725.00n/a2
Apr ’25₹607.00
₹722.50
+19.0%
0.3%₹725.00₹720.00n/a2
Mar ’25₹681.45
₹722.50
+6.0%
0.3%₹725.00₹720.00n/a2
Feb ’25₹616.55
₹730.00
+18.4%
1.4%₹740.00₹720.00n/a2
Jan ’25₹652.35
₹695.00
+6.5%
6.5%₹740.00₹650.00n/a2
Dec ’24₹566.35
₹632.50
+11.7%
2.8%₹650.00₹615.00₹1,000.352
Nov ’24₹546.65
₹632.50
+15.7%
2.8%₹650.00₹615.00₹927.702
Oct ’24₹568.30
₹647.50
+13.9%
0.4%₹650.00₹645.00₹828.102
Sep ’24₹537.85
₹647.50
+20.4%
0.4%₹650.00₹645.00₹861.802
Aug ’24₹590.40
₹737.00
+24.8%
13.2%₹834.00₹640.00₹818.002
Jul ’24₹517.95
₹782.00
+51.0%
6.6%₹834.00₹730.00₹650.752
Jun ’24₹455.95
₹782.00
+71.5%
6.6%₹834.00₹730.00₹612.202
May ’24₹441.80
₹782.00
+77.0%
6.6%₹834.00₹730.00₹644.952
Apr ’24₹429.85
₹782.00
+81.9%
6.6%₹834.00₹730.00₹607.002
Mar ’24₹450.75
₹782.00
+73.5%
6.6%₹834.00₹730.00₹681.452
Feb ’24₹531.75
₹743.33
+39.8%
9.3%₹834.00₹666.00₹616.553
Jan ’24₹618.65
₹743.33
+20.2%
9.3%₹834.00₹666.00₹652.353
Dec ’23₹631.40
₹743.33
+17.7%
9.3%₹834.00₹666.00₹566.353

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 17:28
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Thyrocare Technologies Limited is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alka KatiyarBatlivala & Karani Securities India Pvt. Ltd.
Rahul AgarwalCGS International
Kameswari V. S. ChavaliFirstCall Research